论文部分内容阅读
目的探讨甘精胰岛素在2型糖尿病(T2DM)合并肿瘤患者围手术期应用的效果。方法 T2DM合并食管癌患者51例,随机分为甘精胰岛素组(A组,25例)和胰岛素泵组(B组,26例)。检测并比较降糖相关指标。结果 A组在血糖控制时间、治疗后日平均血糖、胰岛素日使用量、血糖波动程度和胰岛素抵抗指数、低血糖发生率方面与B组比较差异无统计学意义(P>0.05)。A组降血糖日均费用显著低于B组[(36.8±7.6)元vs.(191.7±9.2)元](P<0.05)。结论 T2DM合并肿瘤患者围术期采用甘精胰岛素可以快速、有效、安全控制血糖,日均费用显著低于胰岛素泵降糖。
Objective To investigate the effect of glargine on perioperative patients with type 2 diabetes mellitus (T2DM) with tumor. Methods Totally 51 patients with T2DM and esophageal cancer were randomly divided into insulin glargine group (A group, 25 cases) and insulin pump group (B group, 26 cases). Detection and comparison of hypoglycemic indicators. Results There was no significant difference between group A and group B in blood glucose control time, mean daily blood glucose after treatment, daily insulin dosage, blood glucose fluctuation, insulin resistance index and incidence of hypoglycemia (P> 0.05). The average daily hypoglycemic cost of group A was significantly lower than that of group B [(36.8 ± 7.6) yuan vs. (191.7 ± 9.2) yuan] (P <0.05). Conclusion Gypenosides during perioperative period in patients with T2DM complicated with cancer can control blood sugar rapidly and effectively, and the daily average cost is significantly lower than that of insulin pump.